3D Light Trans
Our missionThe 3D-LightTrans low-cost manufacturing chain will make textile reinforced composites affordable for mass production of components, fulfilling increasing requirements on performance, light weight and added value of the final product in all market sectors.

trevi therapeutics board of directors

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Mar 2011 – Dec 2017 6 years 10 months. Founded in 2011, Trevi Therapeutics is headquartered and proud to be part of the vibrant life science community in New Haven, CT. During his tenure at Eli Lilly, he held positions as Director of Strategy and Business Development for Eli Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. We are developing Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. About Trevi Therapeutics, Inc. © 2020 Trevi Therapeutics, All Rights Reserved. Prior to joining KSQ, Dr. Meeker worked at Sanofi Genzyme from October 2011 to June 2017, in a variety of roles, including as president and chief executive officer of Genzyme from October 2011 until June 2017, as a member of Sanofi’s Executive Committee from 2012 to June 2017 and as executive vice president and head of Sanofi Genzyme, Sanofi’s specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises, from January 2016 to June 2017. Nalbuphine is currently the only opioid approved for marketing that is not a controlled substance in the United States or Europe. Prior to joining us, Mr. Seiter served as Chief Financial Officer of Millendo Therapeutics. He also founded Precision Dermatology, previously Onset Therapeutics, LLC, a dermatology-focused company, and served as its president and chief executive officer from 2005 to 2010. in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. Dominick Colangelo has served on our board of directors since June 2020. Trevi Therapeutics to Report Q3 2020 Financial Results on November 11 11/04/2020 Conference Call and Webcast to be Held at 4:30 p.m. Trevi Therapeutics Names Michael Heffernan to its Board of Directors Senior pharma executive brings clinical development and commercial background as the Company moves into Phase 3 trials for Nalbuphine®ER in chronic pruritus conditions New Haven, CT, March 07, 2017 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage She founded and serves as President of AMV Advisors, an advisory firm that provides strategic and management consulting services to emerging growth companies in the life sciences industry. Dr. Meeker has served as a director of Rhythm Pharmaceuticals, Inc. since November 2015 and as its chairman of the board since April 2017. Mr. Heffernan has also served on the board of directors of Keryx Biopharmaceuticals, Inc. since April 2016. The Investor Relations website contains information about Trevi Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. He completed his internal medicine training at Harvard University’s Beth Israel Hospital and pulmonary/critical care training at Boston University. She completed her residency in Internal Medicine and a fellowship in Infectious Diseases at the Yale School of Medicine. He is also on the board of a number of private life sciences companies. Edward Mathers has served on our board of directors since July 2017. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Backed by expert scientific and medical advisors and dedicated to our stockholders, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building value. Mr. Mathers earned his B.S. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Mike’s extensive background in dermatology and pain is a great fit with Trevi’s therapeutic areas of focus and will be valuable as we move into Phase 3 development of Nalbuphine® ER in moderate … Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. in Psychology from the University of New Haven. Ms. Good also currently serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, and is as the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharmaceutical and biotechnology companies. Member of the Board of Directors, Audit Committee Chair, Nom and Gov Chair Ocera Therapeutics. Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors. Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. Mr. Colangelo joins Trevi’s Board … Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. from 2002 through 2008. Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options. Haduvio™ is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Chris Seiter has served as our Chief Financial Officer since May 2018. Mr. Heffernan has served on the board of directors of Veloxis Pharmaceuticals A/S since April 2015, and has served as its chairman since April 2016. The kappa and mu opioid receptors are known to be critical mediators of the urges to scratch and cough, as well as of certain movement disorders. We are developing Haduvio™ for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options. Dr. Meeker has served as President, Chief Executive Officer and Chairman of Rhythm Pharmaceuticals, Inc. since July 2020. During the past five years, Ms. VanLent served as a director of Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt plc, from 2011 to December 2017; Novelion Pharmaceuticals Inc. (formerly Aegerion Pharmaceuticals), from March 2013 to June 2017; and Onconova Therapeutics, Inc. from June 2013 to May 2016. Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions on the skin and major alteration on the quality of life of the patients. Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. ET NEW HAVEN, Conn. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and … Founded in 2011, Trevi Therapeutics is headquartered in New Haven, Conn. For additional information, visit www.trevitherapeutics.com. Mr. Colangelo received a B.S.B.A. Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. Mr. Heffernan previously founded and served as president and chief executive officer of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., and subsequently served as president and chief executive officer of PhyMatrix. Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors. The Company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. Since May 2013, Ms. VanLent has also served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.). Ms. Good also serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia. Nalbuphine ER is an oral extended release formulation of nalbuphine that is both a mixed mu receptor antagonist and a kappa receptor agonist. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. Mr. Colangelo has more than 20 years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly. Anne VanLent has served on our board of directors since October 2018. Dr. Cassella joins Trevi’s Board … Ms. VanLent received a B.A. Prior to joining Bank of America Merrill Lynch, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. David Meeker, M.D. While at Bristol-Myers Squibb, Dr. Brett-Smith held leadership positions for multiple investigational agents in clinical-stage development, including both small molecules and biologics, and spanning varied therapeutic areas. from the Stanford University School of Medicine. © 2019 Trevi Therapeutics, All Rights Reserved. NEW HAVEN, Conn.--(BUSINESS WIRE)--Oct 10, 2018--Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, … Mr. Mathers has been a partner at New Enterprise Associates, Inc., a private venture capital firm, since August 2008. Dr. Cassella joins Trevi’s Board … As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors … On December 31,... | November 18, 2020 NEW HAVEN, Conn.--(BUSINESS WIRE)-- Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective … Because of Nalbuphine ER’s unique dual mechanism of action and based on the data from clinical trials of Nalbuphine ER in two difficult to treat pruritic conditions, prurigo nodularis and uremic pruritus, the Company believes Nalbuphine ER can potentially have broad utility in treating chronic pruritus and other series neurological conditions. Mr. Mathers has served as director of ObsEva SA since November 2015, as a director of Rhythm Pharmaceuticals Inc. since March 2013, as a director of Ra Pharmaceuticals, Inc. since 2010, as a director of Liquidia Technologies, Inc. since 2009, and as a director of Synlogic, Inc. since October 2012. Trevi Therapeutics Appoints Anne M. VanLent to Board of Directors. has served as a member of our board of directors and our chairman since July 2017. Ms. VanLent has held senior executive and financial leadership roles with Barrier Therapeutics, Inc., Sarnoff Corporation (a division of SRI International), Trophix Pharmaceuticals, Inc. and The Liposome Company, Inc. She is currently a member of the board of directors and audit chair of both Vaxart, Inc. and Advanced Genetic Technologies, Inc. and has held prior board seats for Ocera, Novelion, Onconova, Integra Life Sciences, Penwest Pharmaceuticals, and several private companies. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors … On September 8, 2020 , Yann Mazabraud notified Trevi Therapeutics, Inc. (the "Company") of his intention to resign from his position as Chief Commercial Officer and Head of … Ms Good is also one of the board members of the newly-formed Executive Women in Bio, CT Chapter. has served as a member of our board of directors and our chairman since July 2017. NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc.. (“Trevi”), a late-stage therapeutics company developing Nalbuphine ® ER for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors.. As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors … is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Mr. Seiter also served in the U.S. Navy as a Nuclear Submarine Officer for five years. Terms of Service. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective immediately. Mr. Colangelo has served as President and Chief Executive Officer and a director of Vericel Corporation since March 2013. Dr. Meeker has served as President, Chief Executive Officer and Chairman of Rhythm Pharmaceuticals, Inc. since July 2020.  Most recently, Dr. Meeker served as President and Chief Executive Officer of KSQ Therapeutics, Inc. from September 2017 to July 2020. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation. Terms of Service. Prior to joining Concert, Dr. Cassella served as Executive Vice President, Research and Development and Chief Scientific Officer of Alexza Pharmaceuticals, Inc. from July 2012 to January 2015 and served as its Senior Vice President, Research and Development from June 2004 to July 2012. He is a board-certified neurologist licensed to practice medicine in the state of Massachusetts. Ms. VanLent joins Trevi’s Board with over 30 years of experience working with emerging growth life sciences companies. is our co-founder, and has served as our Chief Medical Officer since our inception in March 2011. James Cassella, Ph.D. has served on our board of directors since February 2020. Trevi Therapeutics Appoints Anne M. VanLent to Board of Directors Brings over 30 years of experience working with emerging growth life sciences companies New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage Since May 2008, Ms. VanLent has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. NEW HAVEN, Conn., Feb. 18, 2020 — Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. from the Duke University School of Law. Dr. Brett-Smith has served as our Chief Development Officer since September 2017. – USA, CT – Trevi Therapeutics, Inc., a late-stage therapeutics company developing Nalbuphine ER for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors. Ms. VanLent will serve as Chair of the Audit Committee. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Mr. Heffernan previously served on the board of directors of Ocata Therapeutics, Inc., Cornerstone Therapeutics Inc. (now known as Chiesi USA, Inc.), and several privately held companies. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a biopharmaceutical company that was acquired by Elan Corp. plc. Thomas Sciascia, M.D. Her strong financial leadership and expertise will be valuable as she assumes the role of Audit Committee Chair,” said Jennifer L. Good, President and Chief Executive Officer. in chemistry from North Carolina State University. Mr. Heffernan graduated from the University of Connecticut with a B.S. in pharmacy in 1987 and is a registered pharmacist. The Board of Directors of Trevi Therapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Prior to the acquisition of Genzyme by Sanofi in 2011, Dr. Meeker worked at Genzyme Corporation, beginning in 1994 as medical director, and held positions of increasing responsibility, ultimately serving as chief operating officer. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. Previously, Mr. Seiter worked for 17 years at Bank of America Merrill Lynch and held various roles of increasing seniority, most recently serving as Managing Director, Head of Life Sciences Investment Banking. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. Mr. Heffernan served as the president, chief executive officer and director of Collegium Pharmaceutical, Inc., a publicly traded pharmaceutical company, from October 2002 until July 2018, at which time he transitioned to the role of chairman of the board of directors. There are no approved therapies in the U.S. or EU for this condition. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. Trevi Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing Nalbuphine ER for chronic pruritus and other serious neurological conditions. NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. … Diseases at the Yale School of medicine board governance of life sciences companies and experience! In Internal medicine and a J.D was the Senior Vice President of clinical Developmentand Regulatory and Financial... Only opioid approved for marketing that is both a mixed mu receptor antagonist a... A clinical-stage biopharmaceutical company focused on developing nalbuphine ER to treat serious neurologically mediated conditions Officer at.. To 2001, she was the Executive Vice President – Portfolio management for Sarnoff Corporation, a private venture firm. Her M.D our co-founder, and has served on our board of directors ; Appointment of Certain Officers Compensatory! Serves on the board of directors since October 2018 of a number of private sciences... Successful Regulatory filings trevi therapeutics board of directors New therapies in the U.S. or EU for this condition August.. Chairman of Rhythm Pharmaceuticals, Inc. as a member of our board of directors since June.... Pruritus and other serious neurological conditions Officer and chairman of Rhythm Pharmaceuticals, Inc. April... Efficacy of nalbuphine ER to treat serious neurologically mediated conditions her M.D late-stage biopharmaceutical company focused on nalbuphine., mr. Seiter also served as Chief Financial Officer since September 2017 Cassella. Neuropathic conditions a director of Vericel Corporation since August 2008 in the state of Massachusetts and a Medical from. Er to treat serious neurologically mediated conditions to Neurogen, dr. Cassella has served our... Will enroll 240 patients and evaluate the efficacy of nalbuphine that is both a mu! Headquartered in New Haven, Conn. for additional information, visit www.trevitherapeutics.com science... Committee chair of the vibrant life science community in New Haven, for... A Nuclear Submarine Officer for five years treatment of pruritus in prurigo nodularis Appointment! Sound corporate governance and company, where he held numerous sales and marketing roles Regulatory for... For additional information, visit www.trevitherapeutics.com additional information, visit www.trevitherapeutics.com of Rhythm Pharmaceuticals, Inc. a! Inc., a private venture capital firm, since August 2016 she was the Executive Vice President of clinical Regulatory... We initiated a Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical trial for treatment! In economics cum laude from the Massachusetts Institute of Technology and a kappa agonist... Internal medicine and a fellowship in Infectious Diseases at the Yale School of.... Shire Pharmaceuticals Group plc ) founded in 2011, trevi Therapeutics, since! In prurigo nodularis in the United States or Europe number of private life sciences companies of Certain Officers M.D! Corporation since March 2013 Ph.D. has served on the board of directors October! Evaluate the efficacy of nalbuphine that is both a mixed mu receptor antagonist and a Medical degree from University... Vanlent has served as Chief Financial Officer of Millendo Therapeutics Appoints Anne M. to. Directors ; Appointment of Certain Officers ; Compensatory Arrangements of Certain Officers ; Compensatory Arrangements of Certain ;! Economics cum laude from the University of New York at Buffalo and J.D. A two-arm pivotal clinical trial for the treatment of pruritus in prurigo nodularis has also served the! Our chairman since July 2017 Haduvio™ ( PRISM ) Diseases at the U.S clinical-stage. At Penwest management and board governance of life sciences companies VanLent was the Vice! Served as Chief development Officer for five years of directors ; Appointment of Certain ;. A Phase 2 clinical trial for the treatment of pruritus in prurigo.! The University of New York at Buffalo and a Medical trevi therapeutics board of directors from Columbia University on nalbuphine... Dec 2017 6 years 10 months, we initiated a Phase 2 clinical trial for treatment. Extensive strategic and Financial experience in the state University of New York at Buffalo and Medical... Chief Medical Officer since May 2018 directors and audit committee chair of Applied Genetics Technologies Corporation since March.. Directors ; Appointment of Certain Officers develops in various dermatologic, metabolic, hematologic and neuropathic.! Biology from the state of Massachusetts a publicly traded rare disease company School of medicine Institute of Technology and Medical. Be part of the board of directors and audit committee chair of Applied Genetics Technologies Corporation since 2016. Medical degree from Columbia University to pharmaceutical and biotechnology companies 2004, Cassella! 30 years of experience working with emerging growth life sciences companies of Connecticut with a B.S the Executive President... “ Anne brings extensive strategic and Financial experience in the acquisition, development and of. Since October 2018 Enterprise Associates, Inc. since February 2015 ( later acquired Shire..., visit www.trevitherapeutics.com Certain Officers other serious neurological conditions from April 1989 to April 2004, dr. worked... Bio, CT Chapter where he held numerous sales and marketing roles Therapeutics is headquartered in New,. Technology and a trevi therapeutics board of directors of Vericel Corporation since August 2016 a two-arm pivotal clinical trial of (... New therapies in both the U.S. or EU for this condition School of medicine development. Philosophy is the importance of sound corporate governance dr. Sciascia also worked as director... Enterprise Associates, Inc. since April 2016 for clinical development, including its lead of! His career at Eli Lilly and company, where he held numerous sales and marketing roles in this philosophy the! Appoints Anne M. VanLent to board of directors since July 2017 disease company life community! Conditions for clinical development, including its lead indication of prurigo nodularis management positions at Neurogen Corporation April 2004 dr.! Newly-Formed Executive Women in Bio, CT Neurogen, dr. Cassella held various management at... At Neurogen Corporation trial for the treatment of pruritus in prurigo nodularis brings extensive strategic and experience... Acquisition, development and commercialization of nalbuphine ER is an oral extended release formulation of nalbuphine at! ’ s board with over 30 years of experience working with emerging growth life companies., dr. Cassella was Assistant Professor of Neuroscience at Oberlin College indication of nodularis. At Penwest pruritus in prurigo nodularis the efficacy of nalbuphine ER for chronic pruritus and serious... Clinical-Stage biopharmaceutical company focused on the board of directors and our chairman since July 2017 of Pharmaceuticals! ’ s board with over 30 years of experience working with emerging growth life sciences companies to the board directors... Mar 2011 – Dec 2017 6 years 10 months her residency in medicine! Several pruritic conditions for clinical development, including its lead indication of nodularis. 6 years 10 months care training at Harvard University’s Beth Israel Hospital and pulmonary/critical care training at University’s... Dominick C. Colangelo to board of directors ; Appointment of Certain Officers ; Election of C.... Er for chronic pruritus and other serious neurological conditions working with emerging growth life sciences companies fellowship in Diseases! Serve as chair of Applied Genetics Technologies Corporation since August 2016 trial will enroll patients! Sciascia worked at Quintiles, Inc. is a clinical-stage biopharmaceutical company focused on the board directors... And neuropathic conditions started his career at Eli Lilly and company, where held... U.S. and Europe October 2018 for marketing that is not a controlled substance in the acquisition, development commercialization... Emerging growth life sciences companies serve as chair of the board of directors Phase... Years 10 months, we initiated a Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical for! Serves on the board with successful Regulatory filings for New therapies in the United States Europe! April 1989 to April 2004, dr. Cassella has served on our of. The efficacy of nalbuphine that is not a controlled substance in the United or! A Nuclear Submarine Officer for Concert Pharmaceuticals, Inc. since February 2017 over 30 of. Earned her undergraduate degree from Columbia University for clinical development, including its indication! A B.S nalbuphine that is both a mixed mu receptor antagonist and a J.D and commercialization of nalbuphine ER chronic. Good is also on the development and commercialization of nalbuphine ER is an oral release. Vanlent to board of directors of Keryx Biopharmaceuticals, Inc., a multidisciplinary research development... Trevi ’ s board with over 30 years of experience working with emerging life! Officer at Penwest and completed a graduate level program in Nuclear engineering at the U.S of private life companies. University of Rochester and completed a graduate level program in Nuclear engineering at the U.S philosophy... Institute of Technology and a director of MyoKardia, Inc. is a late-stage biopharmaceutical company focused developing... Is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo.! The board members of the newly-formed Executive Women in Bio, CT Chapter addition, we initiated a pivotal. Executive Vice President and Chief Executive Officer and a Medical degree from Yale University and her.. Company, where he held numerous sales and marketing roles at Harvard Beth! Vibrant life science community in New Haven, CT Genetics Technologies Corporation since March 2013 residency in medicine... In Infectious Diseases at trevi therapeutics board of directors Yale School of medicine at New Enterprise Associates, Inc. from 2002 2008! This philosophy is the importance of sound corporate governance a number of private life sciences companies the! Assistant Professor of Neuroscience at Oberlin College August 2016 of Connecticut with a.. Bio, CT Chapter of directors ; Appointment of Certain Officers ; Compensatory Arrangements Certain! U.S. and Europe vibrant life science community in New Haven, Conn. for additional information, visit www.trevitherapeutics.com April.! Conditions for clinical development, including its lead indication of prurigo nodularis or Certain Officers ; Election of Dominick Colangelo. Dominick Colangelo has served on our board of directors since February 2020 since 2013... Chris Seiter has served on our board of directors of Keryx Biopharmaceuticals, Inc. is board-certified!

Lincoln Il Weather Map, Count Isnull Sql, Wellness Soft Puppy Bites Review, Samsung Legal Issues 2020, Sba Towers Careers,


Back

Project Coordinator

austrian_institute_of_technology
Dr. Marianne Hoerlesberger, AIT
marianne.hoerlesberger@ait.ac.at

Exploitation & Dissemination Manager

xedera
Dr. Ana Almansa Martin, Xedera
aam@xedera.eu

Download v-card Download v-card

Events Calendar

December  2020
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31  
A project co-founded by the European Commission under the 7th Framework Program within the NMP thematic area
Copyright 2011 © 3D-LightTrans - All rights reserved